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Summary: The entero-insular hormonal axis was studied in eleven conscious Beagle dogs, loaded with glucose
orally and intravenously. In five of them, exocrine pancreatic atrophy was induced by pancreatic duct
occlusion with prolamine, and documented by means of the /?-amino-benzoic acid test. After oral glucose,
the duct-occluded dogs displayed higher blood glucose (log area 4.12 + 0.07 versus 3.76 ± 0.10; p < 0.01),
less plasma insulin (log area 3.56 ± 0.08 versus 3.99 ± 0.08; p < 0.01) and less cholecystokinin-like immu-
noreactivity (log area 2.64 ± 0.09 versus 3.10 ± 0.14; p < 0.01) than controls. In controls, the peripheral
venous insulin concentrations were higher after oral than after isoglycaemic intravenous glucose, and this
difference was no longer demonstrable in duct-occluded dogs. In the latter, gel permeation chromatography
of pool plasma after oral glucose revealed a relative decrease of cholecystokinin-like immunoreactivity species,
which eluted at the positions of sulphated cholecystokinin octapeptide, cholecystokinin-33 and cholecystokinin-
39, and at a position intermediate between these two. Also in the duct-occluded animals, intravenous infusion
of sulphated cholecystokinin octapeptide, in addition to oral glucose, resulted in an increase in plasma insulin
(log area 3.83 ± 0.10 versus 3.64 + 0.06; p < 0.01) and an improvement in oral glucose tolerance. It is
concluded that in the dog
1) the absence of pancreatic acinar tissue is associated with a loss of gastrointestinal factors mediating glucose-
induced insulin secretion, and
2) reduction of circulating endogenous cholecystokinin species may account at least in part for this defect.
Introduction · ι * j r j 1 1 . * Λisolated penlused rat islets in the presence of ade-
Peripheral venous insulin concentrations are higher quately elevated glucose in the medium (6), an effect
after enteral than after parenteral administration of that could be confirmed in the isolated perfused rat
glucose, with both routes producing an equal rise in pancreas using much smaller doses of cholecystokinin-
blood glucose levels. This effect reflects part of the 33 and gastric inhibitory polypeptide (7).
regulatory influence of some intestinal factors upon A , . _ . . , , ,. . , ~ , . . . · An in vivo stimulation of insulin secretion by chole-pancreatic islet functions, known as the entero-m- , . . , ,ON , : «ι · » / < \ r* * · - u-uv ι 4.·^ / ι cystokmm was proposed years ago (8), and since hassular axis (1). Gastric inhibitory polypeptide (or glu- , , , * · * · · · · t_, j ' . ,. . . - Γ . V u been supported by numerous direct and indirect ob-cose-dependent insuhnogemc pep tide) is so far the
best characterized enteric peptide involved in this
effect (1, 2), and it may be not the only one (3-5). ') cholecystokinin-8S = sulphated cholecystokinin octapeptide
cholecystokinin-8 = non-sulphated cholecystokinin octapep-
On the other hand, the combination of gastric inhib- tlde
, . , j ι ι ι · · i\ j j cholecystokmm-4 = cholecystokinin tetrapep tide
itory polypeptide and cholecystokinin1) produced a cholecystokinin-33/39/58 = cholecystokinin (containing 33,
marked increase in the insulin secretory response of 39, 58 amino acids, respectively)
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servations: cholecystokinin receptors are located on
the B-cell (9), exogenous cholecystokinin increases
glucose-induced insulin secretion from islets in vitro
(10 — 13), caerulein and highly purified neutral cho-
lecystokinin stimulate insulinaemia in the dog (14),
mouse (15), and rat (16). However, for the dog, no
data are available on the liberation of endogenous
cholecystokinin by glucose, and its possible molecular
nature.
The present study was performed in a Beagle dog
model with long-term exocrine pancreatic insuffi-
ciency brought about by duct occlusion by prolamine
and subsequent loss of the entero-insular axis of in-
sulin, as demonstrated earlier (17). We evaluated
1) the peripheral blood levels of endogenous chole-
cystokinin in association with the proved lack of
glucose-mediated insulin secretion in occluded dogs;
2) the gel Chromatographie characteristics of circulat-
ing cholecystokinin;
3) the effect of exogenous administration of sulphated
cholecystokinin octapeptide, which is supposed to
possess the full biological activity of cholecystokinin,
on oral glucose tolerance and glucose-mediated in-




Eleven male Beagle dogs with a body weight between 15 and
30 kg, were used after training to Pavlov stands. They were
kept in a controlled environment, had a daily outdoor run, and
were under the supervision of a veterinarian. They were fed
once per day with commercial laboratory diet (Dog meal, Latz
Purina, Emskirchen; FRG) and tap water ad libitum. Surgical
preparations had been performed 3 years previously (17): pan-
creatic duct occlusion (n = 5) by means of an alcoholic prolam-
ine gel (Ethibloc, Ethicon, Norderstedt; FRG), resulting in
complete atrophy of the exocrine pancreas (18), and sham-
operation (n = 6) by laparotomy only. Since surgery, all animals
received pancreatic enzymes (Pankreon, Kali-Chemie, Han-
nover; FRG), 3 g orally once per day (l g represents 12,000
FIP units lipase, 9,000 FIP units amylase, 800 FIP units pro-
teases). None of the dogs had developed steatorrhea or any
sign of intestinal malabsorption during the 36 months obser-
vation period. All function tests were performed with conscious
animals after deprivation of food and enzymes for 24 h.
Exper imental protocol
Exocrine pancreatic function test
The acinar atrophy of the pancreas was monitored by indirect
evaluation of the digestive capacity using the p-amino-benzoic
acid test, which was adapted to the dog (19) and based on serial
measurement of /?-amino-benzoic acid in serum (20). Blood
samples were drawn from an antecubital vein at —20, —10,
30, 60, 90, 120, 150, 180, 210 min. Citrate plasma (0.1 ml Na-
citrate per ml blood) was deproteinised with trichloroacetic acid
.(100 g/1), and supernatants were stored at —20 °C until analysis.
Glucose loads
Oral glucose tolerance was tested by the intragastric instillation
of 1.5 g/kg body weight glucose (dissolved in 100 ml distilled
water). Intravenous glucose was injected as a 400 g/1 solution
into a hindleg vein, using an infusion pump; the dose was
adjusted to produce the same glucose concentration as that
recorded previously in the oral glucose tolerance test in the
same animal; for this purpose it was necessary to monitor the
blood glucose in intervals of 2 — 5 min. Blood samples were
drawn from an antecubital vein at -30, —20, —10, 15, 30, 45,
60, 75, 90, 120, 150, 180 min into pre-chilled tubes containing
1.2 g EDTA and 500 · 103 KIU aprotinin per litre of blood.
Plasma was stored at —20 CC until analysis.
Exogenous cholecystokinin
Animals with pancreatic duct occlusion (n = 4), showing insulin
deficiency in the oral glucose tolerance test (see Results, section
2), underwent two additional oral glucose tolerance tests with
either intravenous administration of cholecystokinin-8S
(Bachern, Bubendorf; Switzerland), 0.05 μg/kg body weight (40
pmol/kg) at 0 min, and subsequent infusion of 0.06 μg (50
pmol)/kg - h over 2 h at a rate of 12 ml/h, or the corresponding
volume of vehicle (see below). The cholecystokinin concentra-
tion measured by radioimmunoassay (see below) at the tube
outlet multiplied by the infusion rate yielded an amount of
transported peptide that was always close to the indicated
calculated dose. The indicated dose was chosen from our own
pilot experiments and literature data, showing that in the dog
infusion of 24 pmol/kg-h and in man infusion of 109 pmol/
kg·h produced plasma levels equivalent to 9 — 10 ng/1 and
approx. 7 ng/1 of standard cholecystokinin-8S, respectively,
above the baseline, when both doses were monitored by bioas-
say (22, 23). For comparison, the increasse of plasma chole-
cystokinin-like immunoreactivity above the baseline, as
achieved with 50 pmol/kg · h cholecystokinin-8S in the present
work, was higher by a factor 1.5 — 2 (see Results), thereby
indicating that our radioimmunoassay (see below) does not
underestimate the circulating cholecystokinin-Jike immunoreac-
tivity after the intravenous infusion of this peptide. The vehicle
consisted of a 1:10 (v: v) mixture of 0.15 mol/1 NaCl and dog
serum freed of cholecystokinin-like immunoreactivity by 30 g/1
microflne precipitated silica (QUSO G 32, Bie & Berntsen,
Aarhus; Denmark). Cholecystokinin-8S was chosen for this
protocol because initial studies revealed that it is no less insu-
linogenic than cholecystokinin-33 on a molar basis. Others (21)
have also reported that synthetic cholecystokinin-8S, natural
canine cholecystokinin-33/39 and cholecystokinin-58 have
equal biological potency.
Chroma t ography
The cholecystokinin-like immunoreactivity (analysis see below)
detectable in plasma after oral glucose loading was separated
into different molecular species using gel filtration (column 1.6
χ 90 cm; Sephadex G 50 superfine, Pharmacia, Uppsala; Swe-
den). In order to prevent degradation, aggregation and non-
covalent binding of cholecystokinin peptides, the column was
eluted at 4 °C with 6 mol/1 urea in 0.1 mol/1 acetic acid. Dextran
Blue and Na125I were used to label the void (V0) and total (Vj)
volume, and insulin (Mr 6000), cholecystokinin-33 (Μτ 3919),
cholecystokinin-8S (Μτ 1143) as markers of peptide elution.
The positions of column markers and of cholecystokinin-like
immunoreactivity in unknown samples (see below) were ex-
pressed as the distribution coefficients (Kd). Owing to shortage
of sample material, only four pool samples were processed [8.4
ml each, made up of plasma aliquots from four sham-operated
and four duct-occluded dogs, respectively], all containing the
peak of cholecystokinin-like immunoreactivity at 60, 75 and 90
min after oral glucose loading. One sample from sham-operated
and one from duct-occluded dogs were extracted (see below),
lyophilized and reconstituted in 2.1 ml eluent. Reconstituted
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sample (1.5 ml) was applied to the column, and the remaining
0.6 ml was assayed directly to monitor recovery from column.
In order to assess whether extraction removes all plasma con-
stituents interfering unspecifically in the cholecystokinin assay
(see below) the other two pool samples from both groups were
first stripped with charcoal (Norit A, Serva, Heidelberg; FRG).
Stripping (130 g charcoal per litre of plasma) completely re-
moved tracer non-sulphated cholecystokinin octapeptide (cho-
lecystokinin-8) and cholecystokinin-8S added to plasma. Ex-
tracts of stripped plasma were then prepared, and assayed both
before and after chromatography, as described above for ex-
tracts of unstripped plasma. In both preparations of the
stripped plasma, i.e. material loaded on to the column and
material eluted from the column, the concentration of chole-
cystokinin-like immunoreactivity was below the detection limit
of the assay (see below). Thus, the assay was apparently free
of unspecific interference, and no further reference will be made
to this in the subsequent text. The stable flow rate was 6 ml/h
(Microperpex pump, LKB Instruments, Bromma; Sweden), the
eluate volume 2 ml. Recovery of cholecystokinin-like immu-
noreactivity from the column was 95 — 105 per cent, after cor-
rection for the assay detection limit. Gastrin was not detectable
(see also below) in the eluates obtained under these conditions.
Analyses
p-Amino-benzoic acid was measured by the Brat ion-Mar shall
method (as modified by Freudiger (26) et al. (19)), glucose by
glucose oxidase (Gluco-Analyzer, Beckman, Fullerton; USA).
Radioimmunoassay procedures were used for the determination
of insulin (plasma (24)), gastrin (plasma (25)), gastric inhibitory
polypeptide [using antibody coded AE 96 (26), and following
essentially the procedure described by the same company], and
cholecystokinin-like immunoreactivity. The latter was extracted
from plasma with 75 — 90 per cent efficiency by two volumes
of ethanol (analytical values for unknown samples are quoted
without correction). The carboxyl-terminal cholecystokinin as-
say, which recognizes the sulphated tyrosyl regions of chole-
cystokinin species, which in turn confer bioactivity to target
organs, has been described previously (27). The rabbit chole-
cystokinin antibody (code C, final dilution 1:100000) shows
almost the same molar sensitivity for detection of cholecysto-
kinin-8S and natural cholecystokinin-33 (recognition sites
amino acid residues 28 — 29), but it is much less sensitive in the
detection of (non-sulphated) cholecystokinin-8 and synthetic
(sulphated) human gastrin-17, as indicated by the relative molar
peptide concentrations capable of displacing 20 per cent of
antibody-bound tracer (taking standard cholecystokinin-8 S as
1.0): cholecystokinin-33 0.85, non-sulphated cholecystokinin-8
2.7, cholecystokinin-4 25, gastrin-17 10. Thus it should be noted
that cholecystokinin-like immunoreactivity values in plasma
represent a mixture mainly of cholecystokinin-8S and chole-
cystokinin-33. Within the framework of our experiments the
slight cross-reactivity with gastrin was negligible, because: gas-
trin peptides are only poorly extracted from plasma by ethanol
(approximately 25 per cent); on a molar basis the rise of serum
gastrin in response to glucose loading is relatively small (fig.
2); and gastrin does not bind to the cholecystokinin antibody
in an acidic and urea-containing environment (see above; chro-
matography). Initially, extracts of hormone-free dog plasma
(see above) were added to the standard curve tubes in amounts
equivalent to tubes containing the unknowns; no change of the
interaction of the standard reference material with the antibody
was observed. The mean sensitivity of the cholecystokinin assay
(10 runs), expressed as per cent tracer binding in the absence
of standard material minus 2 standard deviations, was 2 pg.
The immunoreactivities of hormones correspond to picogram-
equivalents of the respective standard. Detection limits were
(per ml plasma): insulin 2 μΐΐ, gastrin 3 pg; cholecystokinin-
like immunoreactivity 5 pg (corresponding to < 1.2 pmol/1 cho-
lecystokinin-33 and approx. 4.5 pmol/1 cholecystokinin-8S).
Inter- and intra-assay variation coefficients were < 12%.
Calcu la t ions and s ta t is t ics
The difference between the blood levels of hormones after oral
and intravenous glucose loading was considered to reflect the
influence of the entero-insular axis. Integrated values were
calculated from areas above the mean of three baseline values
using the computerized parabolic method. All values are given
as means ± SEM, unless otherwise noted. Based on the distri-
bution type of values the significance of differences (p < 0.05)
was tested by the non-parametric U-test or by the t-test for
paired and non-paired observations (28), as appropriate.
Results
1. General clinical data 36 months af ter pan-
creatic duct occlusion
All animals showed normal eating and drinking be-
haviour throughout the observation period, the mean
body weight in sham-operated dogs increasing from
17.9 ± 1.2 kg (preoperatively) to 21.0 ± 1.9 kg, in
duct-occluded dogs from 16.2 + 0.6 kg (pre-opera-
tively) to 18.5 ±1.4 kg. Fasting blood glucose (sham-
operated dogs: 5.22 + 0.06 mmol/1; duct-occluded
dogs: 5.33 ± 0.06 mmol/1), fasting insulin concentra-
tions (see below), and glucose concentration in spot
urines (sham-operated dogs: 1.11 ± 0.06 mmol/1;
duct-occluded dogs: 1.00 ± 0.06 mmol/1) did not dif-
fer significantly between the two groups. The /?-
amino-benzoic acid test as an indicator of the proteo-
lytic capacity of the exocrine pancreas was signifi-
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Fig. 1. /7-Amino-benzoic acid test for indirect evaluation of the
exocrine pancreatic function in Beagle dogs 36 months
after pancreatic duct occlusion (n = 5, · — ·) and sham-
operated controls (n = 6; O —o). Median and range
(hatched areas) of individual values. I: application of
test meal.
* p < 0.05; ** p < 0.01; sham-operated versus duct-
occluded dogs
2. Plasma glucose and hormones in response
to glucose loads (fig. 2)
Oral glucose load
In sham-operated dogs plasma glucose increased from
the basal level (5.27 ± 0.06 mmol/1) to 10.71 ± 0.61
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Fig. 2. Patterns of blood glucose, insulin, cholecystokinin-like immunoreactivity and gastrin after glucose load (|) in dogs with
pancreatic duct occlusion (n = 5; · — · oral glucose; A — A intravenous glucose) or sham-operated (n = 6; D — D oral
glucose; Δ — Δ intravenous glucose). Glucose concentrations observed with oral glucose approximated closely to those
obtained by intravenous glucose (for details see Methods section). Means ± SEM.
* p < 0.05; ** p < 0.01; duct-occluded versus sham-operated dogs
mmol/1 at 60 min, in duct-occluded dogs from basal
(5.55 ± 0.06 mmol/1) to 14.15 ± 1.00 mmol/1 (60
min). At 30, 60, 75, 150, 180 min the glucose concen-
tration was significantly higher in duct-occluded dogs
than in sham-operated dogs. Plasma insulin increased
from 12 ± 2 mU/1 (basal) to 131 ±27 mU/1 (60 min)
in sham-operated dogs. At 15 until 90 min the duct-
occluded dog group displayed significantly lower in-
sulin concentrations (basal 8 ± 2 mU/1; peak 43 ± 9
mU/1 at 75 min) than the sham-operated dogs group.
Basal plasma cholecystokinin-like immunoreactivity
was 5 ± 1 (sham-operated dogs) and 6 ± 1 (duct-
occluded dogs) ng/1, respectively. In sham-operated
dogs plasma cholecystokinin-like immunoreactivity
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peaked twice (17 ± 2 ng/1 at 30 min; 16 + 2 ng/1 at
90 min). Between 30 and 120 min the cholecystokinin-
like immunoreactivity pattern in the duct-occluded
dog group was at a lower mean level than in the
sham-operated dog group ( 6 + 1 ng/1, p < 0.01, and
6 ± 2 ng/1, p < 0.05, at 30 and 90 min, respectively).
In the sham-operated dog group plasma gastrin in-
creased from basal (14 ± 5 ng/1) to 37 ± 9 ng/1 at 30
min, in the duct-occluded dog group from basal
(12 ± 3 ng/1) to 27 + 3 ng/1 (differences not signifi-
cant). Basal as well as peak values of plasma gastric
inhibitory polypeptide did not differ significantly in
the sham-operated dogs and duct-occluded dog group
(basal: 46 ± 1 and 51 ± 2 ng/1; peak: 958 ± 145 and
989 ± 162 ng/1, respectively).
Intravenous glucose load
Basal plasma glucose before intravenous glucose load
was in the same range as before oral glucose load
(sham-operated dogs: 5.22 + 0.11 mmol/1; duct-oc-
cluded dogs: 5.33 ± 0.11 mmol/1). Figure 2 shows
that the mean glucose values obtained under oral
glucose load closely approximated to the values, ob-
tained by intravenous glucose administration, using
the technique described in the Methods section. The
insulin concentration did not differ significantly be-
tween sham-operated dogs and duct-occluded dogs
throughout the intravenous glucose load (basal level:
sham-operated dogs 13 ± 3 mU/1; duct-occluded
dogs 8 ± 1 mU/1).
Until 120 min the sham-operated dog group displayed
30 — 50% less insulin under intravenous than under
oral glucose load. In contrast, the insulin pattern in
the duct-occluded dog group did not differ signifi-
cantly between intravenous and oral glucose load.
Plasma cholecystokinin-like immunoreactivity did not
increase significantly over the basal level in either the
sham-operated dog group (5 ± 1 ng/1; peak 7 ± 1 ng/1
at 90 min) or the duct-occluded dog group (basal
6 ± 1 ng/1; peak 6 + 1 ng/1 at 90 min). In both groups
plasma gastrin did not rise significantly above the
basal level (sham-operated dogs: 15 ± 5 ng/1; duct-
occluded dogs: 16 ± 2 ng/1). In sham-operated dogs,
up to 75 min after receiving glucose, the gastrin con-
centrations were lower under intravenous than under
oral glucose load (p < 0.05 at 30 and 60 min). A
similar difference was observed in the duct-occluded
dog group up to 90 min after receiving glucose
(p < 0.01 at 75 and 60 min; p < 0.05 at 90 min).
Plasma gastric inhibitory polypeptide did not signif-
icantly rise above the basal level in both groups
(52 ± 1 and 46 ± 2 ng/1 in sham-operated and duct-
occluded dogs, respectively).
3. Integrated glucose and hormones under
the glucose loads (tab. 1)
Under oral, as well as under intravenous glucose load,
duct-occluded dogs displayed significantly increased
integrated glucose compared with sham-operated
dogs. Also under oral glucose load, integrated insulin
and cholecystokinin-like immunoreactivity were sig-
nificantly decreased in the duct-occluded dogs com-
pared with the sham-operated dog group, whereas
under intravenous glucose load no difference in the
Tab. 1. Integrated values of plasma glucose, insulin, cholecys-
tokinin-like immunoreactivity (cholecystokinin) and
gastrin in pancreatic duct-occluded (n = 5) and sham-
operated (n = 6) Beagle dogs after oral and intravenous
glucose; the dose of the latter was adapted so as to





glucose load glucose load
log area/180 min log area/180 min
Glucose Sham- 3.765 ± 0.101 3.794 ± 0.092
operated
Duct- 4.122 ± 0.074** 4.144 ± 0.089**
occluded
Insulin Sham- 3.988 ± 0.079 3.571 ± 0.065
operated
Duct- 3.557 ± 0.077** 3.735 ± 0.070
occluded
Choi- Sham- 3.098 ± 0.143 2.585 ± 0.086
ecysto- operated
kinin Duct_ 2.645 ± 0.095** 2.517 ± 1.164
occluded
Gastrin Sham- 3.590 ± 0.078 3.327 ± 0.143
operated
Duct- 3.553 ± 0.052 3.303 ± 0.105
occluded
p < 0.01 (duct-occluded versus sham-operated dogs)
levels of the two hormones could be found. In the
sham-operated dog group the integrated gastrin was
significantly higher under oral than under intravenous
glucose load. Also in the sham-operated dog group,
the mean integrated gastrin was higher under oral
than under intravenous glucose load, but in the duct-
occluded dog group neither integrated gastrin nor
integrated gastric inhibitory polypeptide (data not
shown) differed statistically under oral and intrave-
nous glucose load.
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4. Entero-insular axis (tab. 2)
The quantitation of the effect of the entero-insular
axis was reflected by the difference (Δ) between hor-
mone concentrations as obtained under oral and in-
travenous glucose load. The duct-occluded dog group
displayed significantly decreased Δ insulin and
Δ cholecystokinin-like immunoreactivity when com-
pared with the sham-operated dog group. Δ gastrin
did not differ significantly between the sham-operated
dogs and duct-occluded dog group. The integrated Δ
insulin and Δ cholecystokinin-like immunoreactivity
were significantly decreased in the latter, whereas in-
tegrated Δ gastrin did not differ statistically between
the two groups. In the sham-operated dog group there
was a significant positive correlation between the
mean values of Δ cholecystokinin-like immunoreac-
tivity and Δ insulin (r = 0.744; ρ < 0.01), and be-
tween the median values of Δ gastrin and Δ insulin
(r = 0.787; ρ < 0.01). In the duct-occluded dog group
such correlations were lacking.
5. Chromatography of cholecystokinin-l ike
immunoreactivi ty in plasma extracts
Total cholecystokinin-like immunoreactivity, ex-
tracted from pool plasma obtained during oral glu-
cose load was 143 pg and 103 pg, for the sham-
operated dogs and duct-occluded dog group, respec-
tively. Regarding the apparent nature of this chole-
cystokinin-like immunoreactivity, three components
were identified, eluting at positions corresponding to
the Mr of cholecystokinin-58 (Kd 0.27), cholecysto-
kinin-33/39 (Kd 0.46/0.54), and cholecystokinin-8S
(Kd 0.83) (tab. 3). The absolute (in pg) and relative
(in per cent) contribution of these species to the total
plasma cholecystokinin-like immunoreactivity after
oral glucose load in the two plasma samples indicate
that in the duct-occluded dog group species of lower
Mr (cholecystokinin-33/39; cholecystokinin-8) were
decreased, whereas species of higher Mr (cholecysto-
kinin-58 and above), were increased (tab. 3). It should
be noted that there were, in addition to the peaks
corresponding to established cholecystokinin molec-
ular species, five intermediate peaks (designated
I i — 15), emerging between the V0 marker and chole-
cystokinin-58 (ΙΟ, the latter and cholecystokinin-33/
39 (I2), cholecystokinin-33/39 and cholecystokinin-8 S
(I3, I4), cholecystokinin-8S and the Vj marker (I5); in
both plasma samples the contribution by these inter-
mediate peaks to the total cholecystokinin-like im-
munoreactivity was greater than that of established
cholecystokinins. In contrast, the reduction (in pg) of
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Tab. 3. Gel permeation chromatography of cholecystokinin (CCK) immunoreactive molecular species in one plasma pool sample
recruited from dogs with pancreatic duct occlusion and one sample recruited from sham-operated control animals; the
two samples correspond to the observation points where the respective plasma samples contained the highest cholecys-
tokinin immuno reactivity concentrations after oral glucose load (60, 75, 90 min). The total cholecystokinin-like immu-
noreactivity eluted was 144.3 and 101.9 pg for the samples from sham-operated and duct-occluded dogs, respectively. I:
intermediate peak; for further details see Methods and Results section. The graph underlying the data of this table is




















































the long-term pancreatic duct occlusion, as depicted
in figure 2, was approximately 33 per cent of both
the intermediate and the established peaks.
6. Plasma glucose and hormones in response
to exogenous cholecystokinin-8S in pan-
creatic duct-occluded dogs (fig. 3, tab. 4)
Plasma glucose increased from the basal level (5.11
± 0.06 and 5.11 ± 0.17 mmol/1) to 11.43 ± 1.33
mmol/1 (60 min) and 13.93 ± 1.94 mmol/1 (60 min)
under cholecystokinin-8S and vehicle, respectively.
Under cholecystokinin-8S, duct-occluded dogs dis-
played a tendency to lower plasma glucose than under
vehicle. There was a 3.5-fold (15 min) and 1.5 — 2-
fold (until 90 min) increase in the insulin concentra-
tion under cholecystokinin-8S compared with vehicle
(basal values: vehicle 12 + 2 mU/1; cholecystokinin-
8S 16 ± 2 mU/1). The mean insulin in sham-operated
dogs under oral glucose load (fig. 3; dotted line) could
not, however, be attained. Within the 2 h infusion
period plasma cholecystokinin-like immunoreactivity
reached a plateau of 11 ±1 ng/1 at 15 min after the
start of infusion (basal level: 6 + 1 ng/1, under both
cholecystokinin-8S and vehicle), but the attained
plasma cholecystokinin-like immunoreactivity re-
mained below the level of that observed for endoge-
nous cholecystokinin-like immunoreactivity in the
sham-operated dog group under oral glucose load
(which was taken as the physiological reference; fig.
3, dotted line). Therefore, an infusion delivering a
higher dose of cholecystokinin-8S [bolus 0.05 g/kg,
infusion 0.09 g (75 pmol)/kg-h] was run together
with oral glucose load. After achieving steady-state,
the mean plasma cholecystokinin-like immunoreactiv-
ity values exceeded those obtained in the sham-op-
erated dog group, but insulinaemia and glucose tol-
erance could not be further improved (data not
shown). Linear regression analysis of the mean plasma
cholecystokinin-like immunoreactivity and insulin re-
sulted in a positive correlation (r = 0.752; p < 0.001).
Under cholecystokinin-8S infusion the integrated glu-
cose was significantly decreased (p < 0.01 and
p < 0.05, respectively; tab. 4), when compared with
data obtained by vehicle infusion.
Discussion
The results of the study show that exocrine pancreatic
atrophy following pancreatic duct occlusion in the
dog was associated in the long-term with normal body
weight, provided that daily enzyme substitution was
maintained. In this situation there were no overt signs
of diabetes. Thus, in the fasting state glucose levels
in blood and urine, as well as plasma insulin levels,
never showed any deterioration. However, when en-
zymes were discontinued (e. g. before commencement
of the present experiments) the /?-amino-benzoic acid
test definitely discriminated duct-occluded dogs with
exocrine pancreatic atrophy from dogs with an intact
pancreas (fig. 1), as documented previously (18). Dur-
ing the experiments, the insulin data in sham-operated
dogs confirmed the well-known difference in periph-
eral plasma insulin concentration between oral and
isoglycaemic intravenous glucose load, whereas duct-
occluded dogs displayed increased plasma glucose and
deficient plasma insulin under oral glucose load. This
lack of insulin in the duct-occluded dogs versus the
sham-operated dog group (fig. 2) points to an im-
pairment of the insulinogenic effect of glucose nor-
mally elicited by the gut under oral glucose load (1).
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Fig. 3. Patterns of blood glucose, insulin and cholecystokinin-like immunoreactivity in pancreatic duct occluded dogs (n = 4;
· — ·) after oral glucose load with either intravenous bolus injection of 8S (j) and subsequent infusion of cholecystokinin-
8S for 2 h, or oral glucose with intravenous bolus injection of vehicle (J,) and subsequent infusion of vehicle for 2 h. The
respective mean values as observed in sham-operated controls after oral glucose load are given for comparison (D—D).
Means ± SEM.
* p < 0.05; ** p < 0.01; cholecystokinin-8S versus vehicle
Tab. 4. Integrated values of plasma glucose, insulin and cho-
lecystokinin-like immunoreactivity (Cholecystokinin) in
pancreatic duct-occluded dogs (n = 4) after oral glucose
superimposed by intravenous bolus and infusion of
sulphated Cholecystokinin octapeptide (cholecystoki-
nin-8S), or after oral glucose superimposed by intra-















p < 0.05; ** p < 0.01 versus vehicle
Available literature data focus on a contributory role
of circulating Cholecystokinin in the control of blood
glucose homeostasis (9, 10, 22, 29). The decreased
plasma cholecystokinin-like immunoreactivity that
was associated with a deficit in glucose-induced in-
sulin in pancreatic duct-occluded dogs, and the sub-
total restoration of normal insulin and glucose con-
centrations and intravenous substitution of cholecys-
tokinin-8S (fig. 3) provide evidence that cholecysto-
kinin is a mediating factor in glucose-induced insulin
secretion in these dogs. Calculation of the difference
between individual values under oral and intravenous
glucose load (Δ) directly yielded values for the gut-
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mediated portion of total insulin, as well as the por-
tion of total cholecystokinin-like immunoreactivity
that may be responsible for the former. Sham-oper-
ated dogs displayed significantly more Δ insulin in
combination with significantly increased Δ cholecys-
tokinin-like immunoreactivity, than duct-occluded
dogs. Also, the significant positive correlation be-
tween Δ cholecystokinin-like immunoreactivity and
Δ insulin seen only in sham-operated dogs supports
the hypothesis that cholecystokinin may have me-
diated the increased insulin secretion in these dogs.
Insulin secretion and oral glucose tolerance in the
duct-occluded dog group could not be further im-
proved by infusion of higher doses of cholecystokinin-
8S, which resulted in even higher-than-normal plasma
cholecystokinin-like immunoreactivity (see Results
section). This observation suggests that cholecysto-
kinin-8S (as well as gastric inhibitory polypeptide; see
Introduction) might be not the only mediator(s) of
glucose-induced insulin secretion, at least in these
pancreatic duct-occluded dogs. Participation of mo-
lecular species of cholecystokinin other than chole-
cystokinin-8S has to be considered, since especially
species of intermediate Mr appeared to be decreased
in the duct-occluded dog group (see below). Of the
species with intermediate Afr, the insulinogenic po-
tency of infused cholecystokinin-33 was no higher
than that of cholecystokinin-8S in the duct-occluded
dog group under oral glucose load (data not shown);
other species, however, were not available to us for
infusion.
Thus, it cannot be excluded that the combined infu-
sion of cholecystokinin-8S and cholecystokinin-33/39,
or of cholecystokinin-8S and cholecystokinin species
yet to be defined, would yield different results with
respect to insulinogenity. The combined infusion of
cholecystokinin-8S and gastric inhibitory polypeptide
was considered to be inappropriate, because the re-
sponse of plasma levels of gastric inhibitory polypep-
tide during either oral or intravenous glucose load did
not differ between the sham-operated dogs and duct-
occluded dog group (see Results, sections 2, 3).
It is necessary to mention that the evaluation of a
gastrointestinal peptide with regard to insulinogenity
demands the comparison of an oral glucose load with
an isoglycaemic intravenous glucose load in the same
individual. In our model cholecystokinin-like immu-
noreactivity showed all criteria claimed for a gastroin-
testinal hormone involved in glucose-induced insulin
secretion (1):
1) release by food, especially glucose;
2) stimulation of insulin secretion in the presence of
elevated blood glucose;
3) plasma concentrations achieved by exogenous in-
fusion did not exceed those obtained after oral food.
Also, recent reports show that oral glucose (29, 30)
and sucrose (30) release cholecystokinin-like immu-
noreactivity, exogenous cholecystokinin releases in-
sulin in the presence of adequate plasma levels of
glucose in vitro (10 — 13), as well as in vivo in the rat
(16) and mouse (15), and finally specific receptors are
located in the islets of Langerhans in the region of B-
cells (9). Thus, from the available information, our
results on the insulinogenic properties of cholecysto-
kinin-like immunoreactivity under oral glucose load
are in agreement with independent observations on
the role of cholecystokinin in glucose homeostasis.
In agreement with previous investigators (31), we were
able to demonstrate in dog plasma, using gel permea-
tion chromatography, the existence of three peaks of
cholecystokinin-like immunoreactivity corresponding
to the Mr of cholecystokinin-8S, cholecystokinin-33/
39, and cholecystokinin-58. Recently, so-called inter-
mediate peaks of cholecystokinin-like immunoreactiv-
ity positioned between those of cholecystokinin-8S
and cholecystokinin-33/39 were detected (32); these
were specified in the dog and thought to represent
cholecystokinin-18 and cholecystokinin-25 (32). In the
present study, the intermediate peaks of cholecysto-
kinin-like immunoreactivity with Mr smaller than cho-
lecystokinin-58 (I2 —Is; tab. 3) theoretically could have
resulted from enzymatic in vitro degradation of cho-
lecystokinin-58 at basic pH (the pH of the cholecys-
tokinin assay buffer was 8.2; (27)). The nature of the
peak Ij eluting before cholecystokinin-58 cannot be
interpreted; it could represent cholecystokinin precur-
sor material or aggregates of smaller fragments. In
order to gain further insight, more studies, including
use of appropriate standard reference peptides and or
region-specific antibodies, are necessary. Any possible
cross-reaction of the cholecystokinin antibody with
gastrin structures, should these have been present in
the fractions in measurable amounts, had been ex-
cluded by the failure of these to react in the gastrin
assay (see Methods section). Also the chromatogra-
phy was carried out under dissociating conditions.
Thus it appears that in the peripheral plasma of the
dog loaded with oral glucose there may exist a cho-
lecystokinin species bigger than cholecystokinin-58
(Mr > 6000). Other authors (33) also reported a peak
located close to V0, detectable by both COOH- and
NH2-oriented antibodies in acid extracts of pig brain
cortex, after gel filtration on Sephadex G-50 sf using
acidic (0.1 mol/1 HC1) column eluent.
We have no adequate explanation for the presence of
the circulating molecular species of cholecystokinin
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possibly responsible for the enhanced plasma insulin
levels after oral glucose load in the sham-operated
dog group, and its absence in the duct-occluded dog
group of our dogs. The overall cholecystokinin-like
immunoreactivity was decreased by approx. 30 per
cent in the latter group. Since in this duct-occluded
dog group there is a 2-fold increase in the percentage
of cholecystokinin-58, in addition to a fall of the
values of biologically active cholecystokinin-33/39
and of the intermediate forms (I3, I4), it is possible
that the degradation of cholecystokinin-58 is impaired
under these conditions; with respect to insulin release,
the biological activity of cholecystokinin-58 is un-
known.
Whether gastrin participates in the glucose-mediated
secretion of insulin is not yet clarified. Exogenous
gastrin in nearly physiological doses potentiated the
plasma insulin concentration under oral glucose load
(34). The results of our present study in the dog agree
with recent observations in man (35): an immediate
but small increase in plasma gastrin under oral glucose
load, as compared with no gastrin change under in-
travenous glucose load (fig. 2). From this and other
observations on gastrin (see Results), gastrin would
appear to play little if any part in the control of the
gut-mediated regulation of peripheral insulin levels in
the dog.
Concluding remarks
A present, the effect of greater insulin concentrations
after oral than after intravenous glucose load, but
with an equal blood glucose concentration under both
regimes, seems to be mediated by a combination of
increased secretion and decreased clearance of insulin
(36); increased secretion is possibly induced by one
or several of the following hormones: gastric inhibi-
tory peptide, cholecystokinin, gastrin, glucagon-like-
peptide 1 (37). Our study provides more specific data
on insulin changes brought about by experimentally
induced alterations of cholecystokinin, which is under
discussion as a possible insulinogenic agent (9, 10, 22,
29). Previously, no animal model was available that
lacked gut-mediated insulin release. The dog with
pancreatic duct occlusion and acinar atrophy is there-
fore the first suitable model for studies on this con-
dition. A possible limitation of this model is that the
intragastric instillation of glucose bypasses the ce-
phalic phase of insulin release which is determined by
the cholinergic vagal tone; also, vagal cholinergic
stimulation sensitizes B cells in response to ingestion
of glucose (38). The decreased insulin and impaired
oral glucose tolerance in the presence of pancreatic
exocrine insufficiency, as demonstrated in this study,
has been known for the duct ligated dog for about
15 years (39), and the same phenomenon was con-
firmed for duct occlusion-mediated insufficiency in
more recent studies in this species (17,40). In contrast,
rats with exocrine pancreatic atrophy display normal
or even improved oral glucose tolerance and insulin
secretion, regardless of the technique in use for in-
ducing exocrine insufficiency (42 — 44). One may spec-
ulate the pancreas functions differ in some species,
for example, with regard to regulation of cholecys-
tokinin release. Thus, cholecystokinin-mediated feed-
back of pancreatic enzyme secretion exists in the rat
(45), but not in the dog with acinar atrophy owing to
pancreatic duct obliteration (46), and its presence is
controversial in man (47, 48). In summarizing our
data, we can conclude that in the dog
1) endogenous cholecystokinin qualifies as a mediator
of glucose-induced insulin secretion;
2) the relative insulinogenic effects of different mo-
lecular species of cholecystokinin-like immunoreactiv-
ity circulating in blood after oral glucose load are
uncertain, but there is evidence that cholecystokinin-
33/39 and fragments intermediate between these and
cholecystokinin-8S are the predominant insulinogenic
species.
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